U.S. Markets close in 4 hrs 37 mins

Lazard Capital previews Q3 earnings in BioPharma space

Lazard Capital believes BioPharma companies most likely to beat Q3 top-line consensus expectations are Questcor (QCOR), Regeneron (REGN), Alexion (ALXN), and Gilead (GILD). The firm raised its price target for Onyx Pharmaceuticals (ONXX) to $110 from $90 and keeps a Buy rating on the stock. Lazard Capital also lowered its price target for Dendreon (DNDN) to $3 from $4 while keeping a Sell rating on shares.